Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,516
  • Shares Outstanding, K 120,285
  • Annual Sales, $ 0 K
  • Annual Income, $ -100,510 K
  • EBIT $ -106 M
  • EBITDA $ -105 M
  • 60-Month Beta 1.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.49
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings $-0.13 on 11/13/25
  • Next Earnings Date 03/30/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 205.76% (-54.54%)
  • Historical Volatility 60.55%
  • IV Percentile 15%
  • IV Rank 18.90%
  • IV High 809.76% on 02/05/25
  • IV Low 65.03% on 10/20/25
  • Expected Move (DTE 20) 0.2295 (40.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 202
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 22,847
  • Open Int (30-Day) 21,058
  • Expected Range 0.3318 to 0.7908

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 6
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5400 +3.94%
on 12/26/25
0.7200 -22.04%
on 12/01/25
-0.1397 (-19.93%)
since 11/26/25
3-Month
0.5400 +3.94%
on 12/26/25
1.1200 -49.88%
on 09/29/25
-0.3778 (-40.23%)
since 09/26/25
52-Week
0.5400 +3.94%
on 12/26/25
1.3900 -59.62%
on 02/21/25
-0.4887 (-46.54%)
since 12/26/24

Most Recent Stories

More News
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...

IMUX : 0.5613 (-3.94%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 0.5613 (-3.94%)
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS  –

IMUX : 0.5613 (-3.94%)
Immunic to Participate in Industry and Investor Conferences in November

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...

IMUX : 0.5613 (-3.94%)
Immunic to Participate in Scientific and Investor Conferences in October

NEW YORK , Oct. 1, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...

IMUX : 0.5613 (-3.94%)
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over...

IMUX : 0.5613 (-3.94%)
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –

IMUX : 0.5613 (-3.94%)
Immunic to Participate in Investor and Scientific Conferences in September

NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule...

IMUX : 0.5613 (-3.94%)
Immunic: Q2 Earnings Snapshot

Immunic: Q2 Earnings Snapshot

IMUX : 0.5613 (-3.94%)
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes,   ...

IMUX : 0.5613 (-3.94%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 0.6499
2nd Resistance Point 0.6236
1st Resistance Point 0.5925
Last Price 0.5613
1st Support Level 0.5351
2nd Support Level 0.5088
3rd Support Level 0.4777

See More

52-Week High 1.3900
Fibonacci 61.8% 1.0653
Fibonacci 50% 0.9650
Fibonacci 38.2% 0.8647
Last Price 0.5613
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar